Friday, December 14, 2018 9:18:22 AM
CVSI TTM Numbers (1 Year ago), Change & Trend
Updated 5 Dec 2018 Stock Price: $4.63 50DSMA = $4.92
Average Price for last period between Q reports = $4.89 (69 days total)
Sales $41.26M. ($16.65M) 148% & rising
Gross Profit $29.8M ($11.1M) 168% & rising
GP Margin 72.22% (66.64%) 8.4% rising slow
Net Income $7.6M (-13.2M) $20.8M & rising
NI Margin 18.42% (NA) & rising
Total Equity $25.7M ($15.3M) 68% & rising fast
Shares Outstanding : 94.4M Far better than most in Industry
SG&A % of Rev. 50%. (93%) Big & improving
Debt: NONE
Cash $11M ($2.3M) & rising fast
Accounts Receivables: $2.5M & growing nicely in proportion to sales.
Prepaid expenses: $1.85M & growing nicely in proportion to sales
Working Capital $18.1M ($4.6M) 293% & rising fast
Working Capital Ratio 7.1 (2.3) & rising fast
FCF & Rate $12.1M 29.4%. (None) & rising fast
Other Numbers to consider:
YTD FCF. $9.6M or 37%. Just WAO
Q3’18 Net Profit Margin: 24.2%
EPS: 8 cents PE = 57.9 a Fact
Fwd Estimated EPS (Next 12 Months) = 20 to 22 cents or 163% (conservative pre FB)
Fwd PE = ($4.63/$0.21) = 22
Market Cap = $437M
Price to Sales Ratio = 10.6 MJ Industry big players = Well above 25
TTM ASGR (Average sequential growth rate Q/Q) = 25.5% (For 148% annual)
TTM ASGR 1 year ago = 13.4% a big improvement.
_____________________________________________________
Nutritional Outlook’s 2018 Best of the Industry Awards, Retail Brand/Product: CV Sciences
http://www.nutritionaloutlook.com/herbs-botanicals/nutritional-outlooks-2018-best-industry-awards-retail-brandproduct-cv-sciences?cid=sm.nuto.site.nosocial&utm_source=t.co&utm_medium=referral
__________________________________________________
The NET effect of institutional investors (The Nasdaq & Farm Bill effect) in a company's stock price.
Watch min 19.00
The Farm Bill & the FDA
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145266066
________________________________________________
CEO Joseph Dowling @ conference call Q2’18
Quote:
Going forward, we are very optimistic about the growth potential for the hemp CBD product category. Industry forecasts estimate that the hemp CBD product category will reach nearly $1.6 billion by 2021(8.4 Times).
While not providing specific guidance, we believe our strong growth will continue, including our ability to generate profitable sales and cash flow. We believe the hemp CBD product category will continue to expand and our ability to grow as the market leader is well-positioned.
The first six months of 2018 have been a great start to the year for our company and we are confident in our ability to deliver a strong second-half to 2018 and believe that we can continue this growth momentum in 2019 and beyond.
Conferencie call Q3’18
Thank you, Debra good afternoon and thanks everyone for joining our call. Earlier today we filed our third quarter 10-Q and earnings press release and we are proud to announce another record financial quarter for the third straight quarter we achieved record revenue, gross profit, cash flow, adjusted EBITDA and net income. The momentum from the first half of 2018 has continued and we anticipate a strong finish for the remainder of the year.
__________________________________________________________
2017 Hemp CBD market sales was $190M. CVSI sold $20.7M
2018 Estimate is $600M
https://wholefoodsmagazine.com/retail-content-library/the-story-of-pluscbd-oil-from-seed-to-shelf/
https://www.fda.gov/food/ingredientspackaginglabeling/gras/
Interesting articles & latest news:
https://www.cnbc.com/video/2018/12/12/farm-bill-may-be-big-win-for-hemp-based-product-manufacturers.html?&qsearchterm=farm%20bill
http://nbr.com/2018/12/12/nightly-business-report-december-12-2018/ (Starts @ min 8:45)
35 Top Revenue Generating Cannabis Stocks Ranked as of November 15th:
https://www.newcannabisventures.com/35-top-revenue-generating-cannabis-stocks-ranked-as-of-november-15th/
https://mmjreporter.com/how-cv-sciences-inc-otcmktscvsi-has-battled-back-against-the-bears/
https://www.streetwisereports.com/article/2018/11/07/hemp-sales-grow-at-cv-sciences-q3-beats-estimates-2019-outlook.html
https://www.nutraingredients-usa.com/Article/2018/11/13/CV-Sciences-says-more-scrutiny-of-CBD-firms-will-make-them-stand-out-as-above-board-player
https://www.thestreet.com/video/cv-sciences-ceo-on-cbd-s-medical-applications-at-jim-cramer-s-teach-in-14748304
Some examples:
https://www.walmart.com/ip/CBD-Spray-500mg-Mint-Poly80-Free-2-OZ/110945292
https://twitter.com/PlusCbdJapan
https://www.thebetterhealthstore.com/cv-sciences-plus-cbd-oil-gold-15mg-60softgels
https://www.swansonvitamins.com/cv-sciences-plus-cbd-oil-gold-formula-15-mg-60-sgels
https://www.palkoservices.com/brand/375/pluscbd-oil
https://www.instacart.com/natural-grocers/products/3406044-plus-cbd-oil-mint-cbd-spray-3mg-2oz-cbd-2-oz
https://www.snaaccbd.com
https://www.scriphessco.com/search/?keyword=plus%20cbd
______________________________________________
https://globenewswire.com/news-release/2018/07/23/1540604/0/en/CV-Sciences-Inc-Files-Application-for-Up-Listing-to-the-NASDAQ-Capital-Market.html
https://soundcloud.com/newcannabisventures/the-drivers-behind-cv-sciences-breakout-quarter-of-123-million-in-cbd-sales
https://www.businessinfocusmagazine.com/2016/03/bringing-cbd-to-the-mainstream/
https://emerginggrowth.com/cv-sciences-otcqb-cvsi-this-hot-cbd-stock-is-a-buy-and-hold-despite-bumpy-ride-to-nasdaq/
https://www.youtube.com/embed/aq4--rIolls
https://www.marijuanabreak.com/cbd/plus-cbd-oil
https://www.facebook.com/pluscbdoil/videos/1974202205985123/
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm
https://ir.cvsciences.com/press-releases/detail/73/cv-sciences-inc-announces-landmark-publication-on-the
https://www.wthr.com/article/new-labeling-rules-now-effect-all-cbd-oil-sold-indiana
https://ir.cvsciences.com/press-releases/detail/81/world-renowned-neurosurgeon-health-and-nutrition-expert
https://www.hindawi.com/journals/jt/2018/8143582/
_________________________________________
Drug development segment:
CV Sciences CFO, Joseph Dowling, discussed the Company's initial drug candidate (CVSI-007),
How CVSI-007 works..
Catalysts for next 2 months :
- Uplisting to the Nasdaq anytime
- Hemp legalization in US (Highly possible) by end of year.
Other Catalysts:
- potential for new products ( New trademarks on the work)
- potential for new BIG RETAIL CHAIN additional stores
- CV-007 IND (early 2019)
_________________________________________________
Explaining the $4.00 Bid price, or the $2.00 - $3.00 minimum closing price for up-listing
Refer to the table in page 10 (Nasdaq Capital Market
Financial and Liquidity Requirements) of the following link:
https://listingcenter.nasdaq.com/assets/initialguide.pdf
At the bottom of the table is written:
Quote:
* Currently traded companies qualifying solely under the Market Value Standard must meet the $50 million Market Value of Listed Securities and the applicable bid price requirement for 90 consecutive trading days before applying.
** To qualify under the closing price alternative, a company must have: (i) average annual revenues of $6 million for three years, or (ii) net tangible assets of $5 million, or (iii) net tangible assets of $2 million and a 3 year operating history, in addition to satisfying the other financial and liquidity requirements listed above.
Conclusion: It is clear that CVSI meets all the criteria under the "Equity Standard" requirements and qualifies under the closing price alternative. The minimum closing price must be $3.00 and does not need to wait 90 days.
Recent GBLX News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/30/2024 09:13:41 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:24:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 07:12:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 09:39:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 10:07:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/10/2023 02:00:29 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM